Aetna Antiemetic Therapy Coverage Update

inv-01: Cancer chemotherapy — primary prophylaxis and treatment

Covered when the following criteria are met for the specified agents and indications

Palonosetron or fosaprepitant: Palonosetron (Aloxi) or fosaprepitant dimeglumine (Emend) is covered for either: (1) prevention of acute nausea or vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, including high-dose cisplatin; OR (2) treatment of chemotherapy-induced nausea or vomiting from low or minimally emetogenic cancer chemotherapy in persons with an inadequate response or contraindication to intravenous granisetron (Kytril) or ondansetron (Zofran) at the FDA recommended dose.

Granisetron/ondansetron IV: Granisetron (Kytril), extended-release granisetron (Sustol) and ondansetron (Zofran) IV therapy are covered for: (1) prevention of acute and delayed nausea and/or vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy including high-dose cisplatin; AND (2) treatment of chemotherapy-induced nausea and/or vomiting from low or minimally emetogenic cancer chemotherapy in persons with an inadequate response or contraindication to oral granisetron (Kytril) or ondansetron (Zofran) at the FDA recommended dose.

Combination palonosetron and fosaprepitant: Combined palonosetron (Aloxi) and fosaprepitant dimeglumine (Emend) is covered for individuals with high emetic risk who have failed previous therapy with a steroid plus a 5-HT3 antagonist.

NK1 antagonists (rolapitant/aprepitant): Use of rolapitant (Varubi) or aprepitant (Cinvanti) in combination with dexamethasone and a 5-HT3 antagonist, administered before IV antineoplastic therapy in adults, is covered for prevention of delayed nausea and vomiting associated with initial and repeat courses of moderate or high emetic risk chemotherapy.

Akynzeo injection (fosnetupitant/palonosetron) in combination with dexamethasone in adults is covered for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

inv-02: Radiotherapy and post-operative indications

Covered when listed conditions and prior therapy failures/contraindications apply

Radiotherapy TBI - Anzemet: Dolasetron mesylate (Anzemet) is covered for prevention of radiation-induced nausea/vomiting secondary to total body irradiation (TBI) when IV granisetron (Kytril) or ondansetron (Zofran) at the FDA recommended dose has failed or is contraindicated.

Radiotherapy TBI - granisetron/ondansetron IV: Intravenous granisetron (Kytril) or intravenous ondansetron (Zofran) is covered for prevention of radiation-induced nausea and/or vomiting secondary to TBI when oral granisetron or ondansetron at the FDA recommended dose has failed or is contraindicated.

Post-operative IV agents: Intravenous palonosetron (Aloxi), dolasetron mesylate (Anzemet) or fosaprepitant dimeglumine (Emend) are covered for prevention or treatment of post-operative nausea or vomiting when intravenous granisetron (Kytril) or ondansetron (Zofran) at the FDA recommended dose has failed or is contraindicated; IV granisetron or ondansetron are covered when oral forms have failed or are contraindicated.

Routine prophylaxis is not recommended when expectation of PONV is low.

inv-03: Pregnancy — severe intractable nausea and vomiting

Covered when ALL of the following are met

Pregnancy criteria: (1) Clinical signs of dehydration are present or nausea/vomiting have persisted for more than 3 weeks; AND (2) Conservative treatment has failed (e.g., dietary changes, ginger, multivitamin, vitamin B6 with or without doxylamine); AND (3) Oral, sublingual, or rectal antiemetics have failed or are contraindicated including 2 or more of: dimenhydrinate (Dramamine), ondansetron (Zofran) or granisetron (Kytril), promethazine (Phenergan), trimethobenzamide (Tigan); AND (4) Other injectable/IV antiemetics have failed or are contraindicated including both dimenhydrinate and promethazine.

When these conditions are met, IV granisetron or ondansetron are covered; IV palonosetron, dolasetron or fosaprepitant are options when IV granisetron or ondansetron at FDA dose have failed or are contraindicated.

inv-04: Experimental / Investigational

Interventions considered experimental/investigational (not covered) due to insufficient evidence

IV dolasetron for chemotherapy: Intravenous dolasetron (Anzemet) for prevention of nausea or vomiting from cancer chemotherapy is considered experimental/investigational and not medically necessary.

FDA safety concerns for IV dolasetron include QT prolongation and risk of torsade de pointes.

IV palonosetron and fosaprepitant for radiotherapy: Intravenous palonosetron (Aloxi) and fosaprepitant dimeglumine (Emend) for prevention of radiation-induced nausea and vomiting are considered experimental/investigational due to insufficient evidence of effectiveness for this indication.

5-HT3 IV for motion sickness: Intravenous 5-HT3 receptor antagonist therapy for motion-induced nausea and vomiting (motion sickness) is considered experimental/investigational.

Aprepitant for gastroparesis:

inv-05: Other indications — refractory non-oncology

Covered when prior failures/contraindications to oral agents documented

Refractory other indications: Intravenous granisetron (Kytril) or ondansetron (Zofran) are covered for refractory nausea/vomiting (e.g., bulimia nervosa, cyclic vomiting syndrome, HIV) when oral granisetron or ondansetron have failed or are contraindicated. Intravenous palonosetron (Aloxi), dolasetron (Anzemet) or fosaprepitant (Emend) are covered when IV granisetron or ondansetron at the FDA recommended dose have failed or are contraindicated.

inv-06: Guideline-based coverage criteria for antiemetic prophylaxis

Covered when regimens align with emetogenic risk and guideline-recommended agents/dosing

Highly emetogenic chemotherapy: Prophylaxis includes an NK1 antagonist (e.g., aprepitant or fosaprepitant), dexamethasone, and a 5-HT3 antagonist; agents should be administered prior to chemotherapy per product labeling.

References: NCCN; Emend prescribing information

Moderately emetogenic chemotherapy: Prophylaxis includes dexamethasone and a 5-HT3 antagonist (palonosetron preferred); consider adding aprepitant for select agents (e.g., carboplatin).

Palonosetron preferred for delayed emesis

Low emetogenic chemotherapy: Non-5-HT3 agents (dexamethasone with or without lorazepam, prochlorperazine, metoclopramide) are acceptable; routine prophylaxis not recommended for minimal-risk regimens.

Radiation-induced emesis:

inv-07: Coverage for NK1-containing antiemetic regimens

Covered when ALL of the following are met

Combination therapy requirement: NK1 agents (fosaprepitant, aprepitant/Cinvanti, rolapitant/Varubi) are used in combination with a 5-HT3 antagonist and dexamethasone for prevention of chemotherapy-induced nausea and vomiting.

Document emetogenicity of chemotherapy and regimen components per prescribing information

Emetogenicity indication: Indication is prevention of CINV for moderately or highly emetogenic chemotherapy or specific highly emetogenic regimens (e.g., high-dose cisplatin, AC-based regimens), or for prevention of delayed nausea/vomiting where NK1 benefit is demonstrated.

NCCN supports adding NK1 for select high-risk patients or prior failure of steroid+5-HT3

Dosing/schedule considerations: Administer NK1 agent per product-specific dosing: fosaprepitant IV dosing varies by emetogenicity (150 mg or 115 mg Day 1 with oral aprepitant follow-on for some regimens); rolapitant dosing is 180 mg oral single dose or 166.5 mg IV infusion; Cinvanti IV dosing per labeling (e.g., 130 mg Day 1 for HEC).

Ensure availability of follow-on oral doses when required (eg, 115 mg fosaprepitant requires confirmed access to Day 2 and 3 oral doses)

inv-08: Coverage for 5-HT3 receptor antagonists

Covered when ALL of the following are met

5-HT3 antagonist use: 5-HT3 antagonists (ondansetron, granisetron, dolasetron, palonosetron) are indicated for prevention of acute CINV and may be used interchangeably at equivalent doses; route selection (oral vs IV) may consider safety and patient circumstance.

Dolasetron injection should not be administered for prevention of CINV due to QT prolongation and torsades risk; tablet formulation may be considered with caution.

inv-09: Aprepitant — gastroparesis evidence

Evidence summary for aprepitant in gastroparesis

Aprepitant gastroparesis randomized trial primary outcome: In a 4-week randomized trial (n=126) of oral aprepitant 125 mg/day versus placebo in patients with chronic nausea/vomiting of presumed gastric origin, aprepitant did not reduce severity of nausea based on the primary VAS outcome (46% vs 40% reduction; RR 1.2; 95% CI 0.8–1.7; p=0.43).

Secondary outcomes showed improvement for some symptom measures; adverse events were more common with aprepitant (35% vs 17%).

inv-10: NEPA (Akynzeo) — CINV

NEPA (netupitant/fosnetupitant + palonosetron) IV and oral safety and effectiveness

NEPA IV vs oral safety: Clinical trials showed IV NEPA had a safety profile similar to oral NEPA with low incidence of treatment-related adverse events, no infusion-site or anaphylactic reactions observed, and no clinically relevant QTc changes in the cited studies.

Akynzeo injection is FDA-approved in combination with dexamethasone for prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapy; not studied for AC regimens in initial approval.

NEPA effectiveness: Single-dose IV or oral NEPA produced high complete response rates in cycle 1 and maintained responses over subsequent cycles in trials (example: cycle-1 overall CR 73.0% IV NEPA vs 77.3% oral NEPA).

inv-11: Aromatherapy — PONV

Aromatherapy for PONV and isopropyl alcohol comparisons

Aromatherapy evidence: A Cochrane review and subsequent systematic reviews provided mixed, generally low-to-moderate quality evidence: aromatherapy did not clearly reduce nausea severity versus placebo, though some analyses suggested fewer rescue anti-emetics; isopropyl alcohol inhalation reduced time to 50% reduction in nausea in some trials.

Overall evidence quality ranged low to very low; findings are uncertain.

inv-12: DEX-sparing regimens with NEPA

DEX-sparing NEPA regimens in older patients fit for cisplatin

DEX-sparing regimen outcomes: In patients >65 years fit for high-dose cisplatin, NEPA plus single-dose dexamethasone (DEX1) or short-course low-dose dexamethasone (DEX3) produced similar complete response rates and patient-reported outcomes compared with standard multi-day dexamethasone (DEX4) in retrospective subset analysis of randomized studies.

Subset included 107 patients >65 years; outcomes similar across DEX regimens.

inv-13: Palonosetron — PDNV

Palonosetron for post-discharge nausea and vomiting (PDNV)

Palonosetron PDNV trial: In a randomized, placebo-controlled trial of high-risk ambulatory surgery patients, IV palonosetron 0.075 mg reduced incidence of PDNV on post-operative days 1 and 2 but did not significantly increase complete response until POD2 versus placebo (48% vs 36%; p=0.131); further investigation was recommended.

The policy lists specific ICD-10 codes that are not considered covered indications under this Clinical Policy Bulletin. Notably, K31.84 (gastroparesis) and the range T75.3xxA–T75.3xxS (motion sickness) are identified as ICD-10 codes not covered for the indications described in this CPB. Additionally, intravenous dolasetron (Anzemet) for prevention of chemotherapy-induced nausea and vomiting is described as experimental/investigational and therefore not supported for that indication.

Safety considerations in the policy highlight that the intravenous formulation of dolasetron (Anzemet) should not be used to prevent chemotherapy-induced nausea and vomiting because of an increased risk of torsades de pointes and other serious cardiac arrhythmias; this injectable formulation is contraindicated for CINV per the FDA. The policy further emphasizes that fosaprepitant (Emend IV) is indicated only for prevention of CINV in patients receiving concurrent moderate- to highly-emetogenic chemotherapy, is not intended as monotherapy, and has specific contraindications and drug-interaction cautions (e.g., medications metabolized by CYP3A4).

Emend (fosaprepitant/aprepitant) is indicated for prevention of chemotherapy-induced nausea and vomiting only when administered as part of a multi-drug prophylactic regimen for patients receiving concurrent moderate- to highly-emetogenic chemotherapy. Emend IV is not indicated for patients who are not receiving concurrent moderate-to-high emetogenic chemotherapy and should not be used as monotherapy; dosing and use should follow the product labeling and ASCO/NCCN guidance.

Akynzeo injection (fosnetupitant/palonosetron) is FDA-approved in combination with dexamethasone for prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapy. The product labeling and the policy note that Akynzeo for injection has not been studied for prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide (AC) regimens, and thus effectiveness and safety for that specific regimen have not been established.

The appendix included with the policy provides an evidence-based classification of antineoplastic agents by their emetogenic potential (high, moderate, low, minimal) to guide selection of prophylactic antiemetic regimens. This appendix is informational in nature and, in the excerpt provided, does not state explicit coverage exclusions; it is intended to assist clinicians in matching antiemetic prophylaxis to the emetogenic risk of specific cancer therapies.

Administrative information and external links are provided for convenience; the document makes clear that Aetna is not responsible for the content, accuracy, or privacy practices of linked non-Aetna sites. Clinical Policy Bulletins offer summary guidance and do not themselves guarantee coverage; providers should consult the main clinical policy and plan documents for complete benefit and authorization details.

The policy states that routine prophylaxis is not recommended for individuals who have little expectation of postoperative nausea and/or vomiting; prophylactic therapy should be targeted to patients with an anticipated risk or those meeting established clinical indications.

Evidence does not support routine repeat dosing of palonosetron (Aloxi) on Days 2–3 following a single-day chemotherapy exposure, nor is routine repeat dosing established for many multi-day chemotherapy regimens. Palonosetron is approved as a single IV dose (0.25 mg) prior to chemotherapy and the need for additional doses in the subsequent days has not been demonstrated to improve outcomes.

Anzemet (dolasetron) injection carries a known risk of QT interval prolongation and torsades de pointes and therefore should not be administered for prevention of CINV; the oral tablet formulation may be considered in certain situations but retains an increased cardiac risk profile. This safety concern led to regulatory guidance restricting the use of intravenous dolasetron for CINV.

Use of aprepitant for gastroparesis is not supported by the primary randomized trial outcome: the randomized study cited did not demonstrate a statistically significant reduction in nausea severity on the primary VAS outcome. Secondary symptom measures showed some benefit, but overall the trial results and subsequent reviews indicate that routine use of aprepitant for gastroparesis remains unsupported by high-quality randomized evidence.

Provider Actions, Prior Authorization and Documentation

Prior Authorization

Prior Authorization Required for Injectable Antiemetics

Prior authorization required for injectable antiemetics when billing the listed HCPCS/J-codes (e.g., J0185, J1260, J1453, J1454, J1456, J1626, J2405, J2469, J2797, J2469). Coverage is contingent on meeting the clinical criteria in this policy (emetogenic risk, prior therapy failures, or pregnancy exceptions).

Affected HCPCS/J-codes: J0185, J1260, J1453, J1454, J1456, J1626, J2405, J2469, J2797
Coverage contingent on meeting policy medical necessity criteria

Prior Authorization

Prior Authorization for NK1 Antagonists

Prior authorization required for NK1 receptor antagonists (e.g., fosaprepitant/Emend, aprepitant/Cinvanti, rolapitant/Varubi) — IV NK1 agents are indicated only in combination with a 5‑HT3 antagonist and dexamethasone and only for prevention of CINV in patients receiving moderate-to-high emetogenic chemotherapy.

NK1 agents must be used as part of a multi-drug antiemetic regimen (NK1 + 5‑HT3 antagonist + dexamethasone)
Emend IV (fosaprepitant) not indicated as monotherapy or without concurrent moderate-to-high emetogenic chemotherapy

Prior Authorization

PA Required for NK1 Agents in Multi‑drug CINV Prophylaxis

When requesting NK1 agents for CINV prophylaxis, prior authorization should document that use is part of a multi‑drug regimen (NK1 + 5‑HT3 antagonist + dexamethasone) and corresponds to the emetogenicity-based regimen (moderate or high). Prior authorization should not be approved for NK1 monotherapy or for indications outside prevention with concurrent moderate‑to‑high emetogenic chemotherapy.

Document regimen components and timing (Day 1 IV dose and planned oral follow-on doses when applicable)
Emend 115 mg IV requires confirmed access to Day 2 and Day 3 oral aprepitant before initiating IV Day 1 dose

Prior Authorization

Prior Authorization for Antiemetic Agents

Prior authorization expectations for antiemetic agents: submit clinical indication, emetogenic risk of the chemotherapy or reason for IV use (e.g., failed or contraindicated oral therapy, severe pregnancy with dehydration), prior medication trials, and planned regimen details (drug names, doses, schedule).

Include emetogenicity classification of chemotherapy agent/regimen (appendix/NCCN)
If for pregnancy, include duration (>3 weeks), dehydration signs, and failure of conservative and oral therapies

Denial Risk

Use of Intravenous Dolasetron (Anzemet)

Intravenous dolasetron (Anzemet) is not covered for prevention of nausea and vomiting from cancer chemotherapy and is considered experimental/investigational for this indication due to safety concerns.

HCPCS: J1260 (injection, dolasetron) noted in code list but IV dolasetron for CINV is considered experimental/not covered per policy
FDA safety warning: IV dolasetron increases risk of torsades de pointes

Denial Risk

Dolasetron IV Safety — Not Covered for CINV

IV dolasetron mesylate carries a documented safety risk (QT prolongation/torsades). The FDA recommends it should not be used to prevent CINV in pediatric and adult patients; therefore IV dolasetron is contraindicated for CINV prophylaxis and will not meet medical necessity.

Documented FDA advisory: increased risk of fatal arrhythmia (torsades de pointes)
IV dolasetron for CINV is listed as experimental/investigational and not medically necessary

Documentation Required

Contraindications and Required Access to Follow‑on Oral Doses

For NK1 IV agents with multi-day oral follow-on therapy (e.g., Emend 115 mg IV followed by oral aprepitant), ensure the member has confirmed access to Day 2 and Day 3 oral doses prior to authorizing the Day 1 IV dose; contraindications (pimozide, terfenadine, astemizole, cisapride) and hypersensitivity to components (polysorbate 80) must be assessed.

Confirmed access to Day 2/3 oral aprepitant required for 115 mg IV Emend
Do not use in patients on pimozide, terfenadine, astemizole, cisapride, or with hypersensitivity to product components

Note

No Explicit Prior Authorization or Billing Denial Triggers Specified

This policy excerpt does not specify a universal list of administrative prior‑authorization triggers or automated billing denial rules; consult the payer's main Clinical Policy Bulletin or benefits/contracts for specific PA process, required forms, and billing denial triggers.

No explicit PA workflow or automated denial triggers are described in this section
Providers should verify plan-specific prior authorization procedures before billing

Denial Risk

No Denial Triggers Specified in These Sections; Clinical Exclusions Apply

The excerpt does not list specific denial triggers tied solely to the clinical content beyond the drug-specific exclusions (e.g., IV dolasetron not covered, NK1 without appropriate regimen). Use of agents outside listed indications or without required documentation may result in denial.

Denials likely when IV agents are used outside FDA‑approved indications or policy criteria (e.g., NK1 monotherapy, IV dolasetron for CINV)
Provide full documentation to avoid denial

Documentation Required

Pregnancy IV Antiemetic Documentation

Pregnancy: documentation required for IV antiemetic use — severe, intractable, persistent nausea/vomiting with clinical signs of dehydration or symptoms >3 weeks, failure of conservative measures, failure/contraindication to oral/sublingual/rectal agents (≥2 agents), and failure/contraindication to other injectable agents (all listed).

List prior conservative treatments tried (dietary changes, ginger, vitamin B6, doxylamine)
Document trials/failures of ≥2 oral antiemetics and failure/contraindication to injectable agents

Documentation Required

Indication and Dosing Documentation

Indication and dosing documentation should support the specific clinical scenario: emetogenicity of chemotherapy (moderate/high), dose and timing per product labeling (e.g., palonosetron 0.25 mg IV 30 minutes prior to chemotherapy; fosaprepitant 150 mg IV 30 minutes prior in combination regimens), and planned adjunctive corticosteroid and 5‑HT3 agent.

Document product dosing and timing per prescribing information (Aloxi, Emend, Cinvanti, Akynzeo)
For Emend/fosaprepitant, document combination with dexamethasone and a 5‑HT3 antagonist

Documentation Required

Regimen and Emetogenicity Documentation

Regimen and emetogenicity documentation: prior authorization requests must show the chemotherapy emetogenic risk and that the antiemetic regimen follows NCCN-based sequencing (e.g., add NK1 for high-risk or select moderate-risk patients, palonosetron preferred for moderate risk). Escalation to an NK1 agent should be documented for patients with inadequate control on steroid + 5‑HT3 antagonist or with additional risk factors.

State prior antiemetic regimens and clinical response (inadequate control warrants NK1 addition)
Reference NCCN emetogenicity classification and rationale for escalation

Documentation Required

Akynzeo Injection Prescribing Note

Akynzeo injection (fosnetupitant/palonosetron) is FDA‑approved for prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapy in combination with dexamethasone; include this prescribing-note when requesting coverage for Akynzeo IV.

Akynzeo injection indicated in adults in combination with dexamethasone for HEC
Not studied for anthracycline plus cyclophosphamide regimens per labeling

Documentation Required

Documentation Note — CPB Scope

Documentation note: Clinical Policy Bulletins summarize plan benefits and clinical criteria but do not guarantee coverage. Providers remain responsible for submitting complete clinical documentation to support medical necessity and must confirm member benefits and PA requirements with the plan.

CPBs are a partial description of benefits and not a contract or guarantee of coverage
Confirm member-specific benefits and authorization procedures prior to treatment

Step Therapy

Step Therapy — Informational

No step‑therapy mandates are specified in this excerpt. The policy describes stepwise/sequence-based clinical approaches (e.g., IV palonosetron or fosaprepitant allowed for prevention; dexamethasone‑sparing NEPA options) but does not impose administrative step‑therapy or prior trials beyond the clinical criteria already listed.

Informational only: describes clinical sequencing and DEX‑sparing regimens (NEPA)
Providers should follow clinical criteria; check payer for any separate step‑therapy programs

Note

Emetogenic Risk‑Based Regimen Sequencing

Emetogenic risk‑based regimen sequencing: antiemetic regimens should follow emetogenic risk stratification (minimal, low, moderate, high) consistent with NCCN guidance — e.g., NK1 + 5‑HT3 + dexamethasone for high risk; palonosetron preferred for moderate risk; no routine prophylaxis for minimal risk.

Specify the emetogenicity classification of the chemotherapy when requesting prophylactic IV antiemetics
Use NCCN guidance to justify regimen selection (appendix lists agents by emetogenic potential)

Prior Authorization

Escalation to NK1 Agent After Inadequate Control or High‑Risk Scenarios

Escalation to an NK1 agent: add an NK1 (aprepitant/fosaprepitant/rolapitant) to dexamethasone + 5‑HT3 antagonist for select patients who have inadequate control with steroid + 5‑HT3 or who have additional risk factors (e.g., regimens such as carboplatin, cyclophosphamide, doxorubicin, epirubicin, ifosfamide, irinotecan, methotrexate). Document prior therapy failure and rationale for escalation.

Document prior steroid + 5‑HT3 use and inadequate response
List specific risk factors or high‑emetic‑risk agents prompting NK1 addition

Background and Definitions

5-HT3 receptor antagonists (including palonosetron, dolasetron, granisetron, and ondansetron) act by blocking serotonin at vagal afferents and central emesis pathways and are used to prevent and treat postoperative and therapy-related nausea and vomiting. Palonosetron is a second-generation 5-HT3 antagonist with a longer half-life and demonstrated efficacy for both acute and delayed chemotherapy-induced nausea and vomiting.

5-HT3 receptor antagonists — class description and examples

Class definition5-HT3 receptor antagonists block serotonin (5‑HT3) binding at vagal afferents in the gut and in CNS regions involved in emesis, preventing and treating postoperative and therapy-related nausea and vomiting.

Examples (intravenous and oral)Palonosetron (Aloxi), dolasetron mesylate (Anzemet), granisetron (Kytril), ondansetron (Zofran)

Typical usesPrevention and treatment of CINV, radiation‑induced nausea/vomiting, and PONV; choice guided by emetogenic risk and patient factors.

Emetogenic risk categories — Classification used to guide antiemetic prophylaxis

PurposeClassification of chemotherapy agents by likelihood of causing emesis (high, moderate, low, minimal) used to guide selection of antiemetic prophylaxis per practice guidelines.

High-risk implicationRegimens with >90% emesis risk — recommend multi‑drug prophylaxis (NK1 antagonist + dexamethasone + 5‑HT3 antagonist).

Highly emetogenic chemotherapy — Definition and implications for multi-drug prophylaxis

DefinitionHighly emetogenic chemotherapy: regimens with a high likelihood of causing nausea/vomiting that warrant multi‑drug prophylaxis (typically an NK1 antagonist + dexamethasone + a 5‑HT3 antagonist).

Clinical implicationPatients receiving HEC should receive guideline‑based combination prophylaxis given prior to chemotherapy and for delayed phase as specified by product labeling.

Examples notedHigh‑dose cisplatin and other regimens specifically identified in guideline/labeling as highly emetogenic warrant NK1 inclusion.

Palonosetron (Aloxi) — Pharmacology and dosing summary

PharmacologyPalonosetron is a second‑generation selective 5‑HT3 receptor antagonist with a long elimination half‑life (~40 hours) and minimal affinity for other receptors.

IndicationsIndicated for prevention of acute and delayed CINV with moderately and highly emetogenic chemotherapy and for prevention of PONV up to 24 hours post‑surgery.

Dosing (IV)CINV prophylaxis: 0.25 mg IV as a single dose approximately 30 minutes before start of chemotherapy; PONV prophylaxis: 0.075 mg IV immediately before induction of anesthesia.

5-HT3 antagonist — Class definition

Class definition5‑HT3 antagonist: agents that block the 5‑hydroxytryptamine‑3 receptor to prevent and treat nausea and vomiting, particularly chemotherapy‑induced and postoperative emesis.

Common agentsOndansetron, granisetron, dolasetron, palonosetron

Clinical noteAt equivalent doses, 5‑HT3 agents have comparable efficacy for acute emesis; route selection considers safety (e.g., IV dolasetron injection contraindicated for CINV) and cost.

NK1 receptor antagonist — Class definition and examples

Class definitionNK1 receptor antagonists are substance P/neurokinin‑1 antagonists that inhibit emesis via central NK1 receptor blockade and are used to prevent delayed phase CINV in combination regimens.

ExamplesAprepitant (Emend/Cinvanti), fosaprepitant (Emend IV), rolapitant (Varubi)

Use caseAdministered with a 5‑HT3 antagonist and dexamethasone for prevention of acute and delayed nausea/vomiting with moderate to highly emetogenic chemotherapy per labeling and guidelines.

Minimal-risk emetogenic agents — Definition and examples (appendix)

DefinitionMinimal‑risk emetogenic agents: cancer drugs associated with <10% frequency of emesis in the absence of effective antiemetic prophylaxis.

GuidanceFor agents in this category no routine prophylactic antiemetic therapy is recommended per NCCN guidance; agents are listed in the appendix (NCCN, 2019).

Examples (appendix source)Multiple agents listed in the appendix including many targeted and lower‑emetic‑potential drugs (see NCCN appendix for full list).

Recommended and Covered Antiemetic Regimens

inv-62: first-line — top-level node for first-line regimens (CINV prophylaxis context)

first-line: For highly emetogenic chemotherapy include aprepitant (or fosaprepitant IV), dexamethasone, and a 5-HT3 antagonist (with or without lorazepam) as first-line prophylaxis per guideline recommendations.

inv-63: first-line — single top-level node (CINV prophylaxis)

first-line: For moderately emetogenic chemotherapy, first-line prophylaxis includes dexamethasone plus a 5-HT3 antagonist (palonosetron preferred); consider adding aprepitant for select agents.

inv-64: first-line — top-level node describing initial regimen choices

initial regimen choices: Initial prophylaxis for moderate-to-high emetogenic chemotherapy should follow guideline-specified combinations (NK1 antagonist + 5-HT3 RA + dexamethasone for highly emetogenic; palonosetron preferred for moderate emetogenic regimens).

Per NCCN and Emend labeling

inv-65: first-line — first-line node emphasizing NK1 agent addition when indicated

NK1 addition when indicated: Add an NK1 agent (aprepitant, fosaprepitant, or rolapitant) to dexamethasone plus a 5-HT3 antagonist for select high-risk patients or after inadequate control with steroid plus 5-HT3 therapy; administer NK1 agents prior to each chemotherapy cycle per product labeling.

inv-66: informational — NEPA/DEX-sparing trial outcomes and context

NEPA informational: NEPA (netupitant/palonosetron) IV and oral formulations demonstrated similar safety and effectiveness in trial programs with maintained complete response rates over cycles and no infusion-site or anaphylactic reactions reported in cited studies.

Informational; relates to Akynzeo approval and trial outcomes.

Regimen	Indication / Notes
Aprepitant + dexamethasone + 5-HT3 antagonist (with/without lorazepam)	Prophylaxis for highly emetogenic chemotherapy; recommended by NCCN as the antiemetic regimen for highly emetogenic drugs.
Combined palonosetron and fosaprepitant	Option for individuals with high emetic risk who have failed prior steroid plus 5-HT3 antagonist therapy.

Regimen	Indication / Notes
Dexamethasone + 5-HT3 antagonist (palonosetron preferred)	Recommended prophylaxis for moderately emetogenic chemotherapy; consider adding aprepitant for selected agents (eg, carboplatin).

Agent / Dosing	Administration / Notes
Fosaprepitant 150 mg IV (Day 1)	Administer IV over 20–30 minutes ~30 minutes prior to chemotherapy in combination with dexamethasone and a 5‑HT3 antagonist for moderately and highly emetogenic regimens per prescribing information.
Fosaprepitant 115 mg IV (Day 1)	Used for certain regimens (MEC/HEC) as specified; when 115 mg is used, protocol includes follow-on oral aprepitant on Days 2–3—ensure availability of oral doses.
Aprepitant (Cinvanti) IV 130 mg single dose (HEC)	IV single-dose regimen for highly emetogenic chemotherapy: 130 mg on Day 1 as an infusion ~30 minutes prior to chemotherapy, given with dexamethasone and a 5‑HT3 antagonist.
Aprepitant (Cinvanti) IV 100 mg single dose (MEC) + oral Days 2–3	Moderately emetogenic chemotherapy regimen: 100 mg IV on Day 1 with oral aprepitant (80 mg) on Days 2 and 3, plus dexamethasone and a 5‑HT3 antagonist per product labeling.
Rolapitant oral 180 mg single dose	Oral rolapitant 180 mg given as single dose in combination with a 5‑HT3 antagonist and dexamethasone for prevention of delayed CINV.
Rolapitant IV 166.5 mg infusion	IV rolapitant (ready-to-use emulsion) administered as single infusion in combination with a 5‑HT3 antagonist and dexamethasone per product information.

Product / Dose	Indication / Timing
Palonosetron (Aloxi) 0.25 mg IV single dose	Prophylaxis for acute and delayed chemotherapy-induced nausea and vomiting; administer as a single 0.25 mg IV dose ~30 minutes prior to chemotherapy.
Palonosetron (Aloxi) 0.075 mg IV single dose	Prophylaxis for postoperative nausea and vomiting (PONV); administer 0.075 mg IV immediately before induction of anesthesia (effective up to 24 hours).

Agent	Dosing / Combination Use
Fosaprepitant (Emend)	Available as IV 115 mg or 150 mg doses for Day 1 administration; used in combination with dexamethasone and a 5‑HT3 antagonist for prevention of acute and delayed CINV per prescribing information.
Aprepitant (Cinvanti)	IV single-dose regimens: 130 mg on Day 1 for HEC; 100 mg on Day 1 for MEC with oral aprepitant (80 mg) on Days 2–3 as specified; used with dexamethasone and a 5‑HT3 antagonist.
Rolapitant (Varubi)	Available as oral 180 mg single dose or IV 166.5 mg infusion; given in combination with a 5‑HT3 antagonist and dexamethasone for prevention of delayed CINV.

Regimen	Outcome / Notes
NEPA (netupitant/palonosetron) + single-dose dexamethasone (DEX1)	DEX-sparing regimen evaluated in older patients fit for cisplatin; single-dose DEX with NEPA produced similar complete response rates and patient-reported outcomes compared with standard multi-day dexamethasone.
NEPA + short-course low-dose dexamethasone (DEX3)	Short-course low-dose dexamethasone (days 2–3) with NEPA also showed non-inferior effectiveness versus standard multi-day DEX in the cited subset analyses.

Emetogenic Category	Examples / Source
High (greater than 90% frequency of emesis)	Examples listed in Appendix (eg, cisplatin ≥50 mg/m2, AC combination, dacarbazine); source: NCCN, 2019.
Moderate (30–90% frequency of emesis)	Appendix provides multiple agents classified as moderate risk (eg, carboplatin, oxaliplatin); source: NCCN, 2019.
Low (10–30% frequency of emesis)	Appendix lists many agents categorized as low risk; source: NCCN, 2019.
Minimal (less than 10% frequency of emesis)	Appendix lists agents considered minimal-risk (see minimal-risk table); source: NCCN, 2019.

Minimal-risk Agents	Notes / Source
Agents considered minimal-risk (examples)	Appendix lists multiple agents considered minimal-risk (eg, alemtuzumab, asparaginase, atezolizumab, avelumab, bevacizumab, bleomycin, etc.); classification from NCCN 2019.

C9145	Injection, aprepitant, (aponvie), 1 mg
J0185	Injection, aprepitant, 1 mg
J1260	Injection, dolasetron mesylate, 10 mg
J1453	Injection, fosaprepitant, 1 mg
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
J1456	Injection, fosaprepitant (teva), not therapeutically equivalent to J1453, 1 mg
J1626	Injection, granisetron HCl, 100 mcg
J2405	Injection, ondansetron HCl, per 1 mg
J2469	Injection, palonosetron HCl, 25 mcg
J2797	Injection, rolapitant, 0.5 mg

Q0162	Ondansetron 1 mg, oral, FDA-approved presecription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0166	Granisetron HCl, 1 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 24-hour dosage regimen
Q0180	Dolasetron mesylate, 100 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 24-hour dosage regimen

B20	Human immunodeficiency virus [HIV] disease
F50.2	Bulimia nervosa
O21.0 - O21.9	Excessive vomiting in pregnancy [when clinical signs of dehydration are present or nausea and vomiting have persisted more than 3 weeks and criteria A,B, and C are met]
R11.0	Nausea
R11.10 - R11.14	Vomiting
T66.xxx+	Radiation sickness, unspecified [nausea or vomiting secondary to total body irradiation]
Z51.0	Encounter for antineoplastic radiation therapy [for total body radiation when oral antiemetic therapy has failed or is contraindicated]
Z51.11 - Z51.12	Encounter for antineoplastic chemotherapy and immunotherapy [for total body radiation when oral antiemetic therapy has failed or is contraindicated]
K31.84	Gastroparesis
T75.3xxA - T75.3xxS	Motion sickness

R11.11	Vomiting without nausea
R11.12	Projectile vomiting
R11.2	Nausea with vomiting, unspecified
T45.1X5+	Adverse effect of antineoplastic and immunosuppressive drugs [not covered for Anzemet]
T66.xxx+	Radiation sickness, unspecified
Z51.0	Encounter for antineoplastic radiation therapy
Z51.11	Encounter for antineoplastic chemotherapy
Z51.12	Encounter for antineoplastic immunotherapy
K31.84	Gastroparesis
T75.3xxA - T75.3xxS	Motion sickness

OpenPayer

Antiemetic Therapy

Coverage Criteria for Antiemetic Therapy

Coding and Emetogenic Classification

Provider Actions, Prior Authorization and Documentation

Background and Definitions

Recommended and Covered Antiemetic Regimens

Line of Therapy Considerations